Grant✓ Small businesses may apply
National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)
National Institutes of Health
- Opportunity #
- PAR-25-353
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.242
- Status
- posted
- Posted
- Jan 15, 2025
- Closes
- Oct 25, 2027
- Funding instrument
- Cooperative Agreement
- Category
- Health
- Cost sharing required
- No
Who can apply
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •State governments
- •Independent school districts
- •City or township governments
- •Special district governments
- •Public and State controlled institutions of higher education
- •For profit organizations other than small businesses
- •Native American tribal governments (Federally recognized)
- •Private institutions of higher education
- •County governments
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •Public housing authorities/Indian housing authorities
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •Small businesses
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Synopsis
Reissue of PAR-20-119. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, substance use disorders (SUDs) or alcohol use disorder (AUD), and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This FOA supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. Projects seeking support for a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies should consider the companion U01 FOA.
Contact
National Institutes of Health · grantsinfo@nih.gov